Ep. 126 - Growing Galapagos, Plus Abortion & Biopharma - BioCentury This Week

Om avsnittet

On the latest BioCentury This Week podcast, a pair of deals demonstrates how Galapagos CEO Paul Stoffels is shifting the Belgian biotech’s strategic focus from small molecules toward a diversified portfolio. Plus: why Friday’s Supreme Court decision to overturn Roe v. Wade sets the stage for legal and legislative battles that could have broad implications for biopharma and how a new crop of Indian biotechs are seeking to offer dramatically cheaper CAR T therapies. This week’s podcast is sponsored by the BioCentury-BayHelix East-West Summit 2022.

Reach us by sending a text

Ep. 126 - Growing Galapagos, Plus Abortion & Biopharma

Om avsnittet

Fler avsnitt

Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways

Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Ep. 384 - Back to School Special: The global FIH trials race

Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA